Ondine Biomedical Inc.

Board/Management Information • Jan 31, 2025

National Storage Mechanism | Additional information

RNS Number : 4550V

Ondine Biomedical Inc.

31 January 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine CEO increases stake in Company as Phase 3 clinical trial is underway

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments to treat and prevent multidrug-resistant infections, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 200,775 shares ("Common Shares") in the Company at a price of 12 pence per Common Share on 30 January 2025. 

Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,064,804 Common Shares representing 35.3057% of the issued share capital of the Company.

Enquiries:

Ondine Biomedical Inc.	www.ondinebio.com
Carolyn Cross, CEO	Via Vane Percy & Roberts
Singer Capital Markets (Nominated Adviser and Joint Broker)
Phil Davies, Sam Butcher	+44 (0)20 7496 3000
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	+44 (0)20 7653 4000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Carolyn Cross and her PCA
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer (PDMR)
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ondine Biomedical Inc.
b)	LEI	9845005B69E07CGF4A56
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Common shares
Identification code	ISIN: CA68234M2058
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	200,775 shares at 12 pence each
d)	Aggregated information: ·Aggregated volume ·Price	N/A
e)	Date of the transaction	30 January 2025
f)	Place of the transaction	AIM

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZGFMLMFGKZG